Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis

Clinical and Experimental Nephrology

Volumn 12, Issue 1, 2008, Pages 33-40

  Mori Takeyama, Urara ^a   Minatoguchi, Shinya ^a   Murata, Ichijirou ^a   Fujiwara, Hisayoshi ^a   Ozaki, Yoko ^b   Ohno, Michiya ^b   Oda, Hiroshi ^b   Ohashi, Hiroshige ^b  

^a GIFU UNIVERSITY   (Japan)

^b GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

Author keywords

Benazepril; Candesartan; Chronic glomerulonephritis; Dual blockade; Proteinuria; Renal function

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; BENAZEPRIL; CANDESARTAN; CANDESARTAN HEXETIL;

ADULT; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZAZEPINES; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 38549100266     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-007-0013-6     Document Type: Article

References (33)

1. Mashio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of angiotensin-converting-enzyme inhibitor benazepril on chronic renal insufficiency. N Engl J Med. 1996;334:939-45.
2. Remuzzi G, Ruggenenti P, Perico N. Chronic renal disease: renoprotective benefits of rennin-angiotensin system inhibition. Ann Intern Med. 2002;136:604-15.
3. Weir MR. Progressive renal and cardiovascular disease: optimal treatment strategies. Kidney Int. 2002;62:1482-92.
4. Yu HT. Progression of chronic renal failure. Arch Intern Med. 2003;163:1417-29.
5. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Jong PE, et al. Antiproteinuric effect of blood-pressure-lowerling agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963-74.
6. Hilgers KF, Mann JF. ACE inhibitors versus AT(1) rexeptor antagonists in patients with chronic renal disease. J Am Soc Nephrol. 2002;13:1100-8.
7. Taal M, Brennner B. Combination ACE inhibitor and ARB therapy: additional benefit in renoprotection. Curr Opin Nephrol Hypertens. 2002;11:377-81.
8. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, et al. Additive antiproteinuric effect on converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999;33:851-6.
9. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Batteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European group fot the investigation of valsartan in chronic renal disease. J Hypertens. 2000;18:89-95.
10. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual rennin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002;62:1020-5.
11. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003;361:117-24.
12. Campbell R, Sangalli F, Perticucci, Aros C, Viscarra C, Perna A, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 2003;63:1094-103.
13. Thurmann JM, Schrier RW. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med. 2003;114:588-98.
14. Kincaid-Smith P, Fairely KF, Packham D. Dual blockade of the rennin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. Nephrol Dial Transplant. 2004;19:2272-4.
15. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18-25.
16. Iodice C, Balletta M, Minutolo R, Giannattasio P, Tuccillo S, Bellizzi V, et al. Maximal suppression of rennin-angiotensin system in nonproliferative glomerulonephritis. Kidny Int. 2003;63:2214-21.
17. Keilani T, Danesh F, Schlueter W, Molteni A, Batlle D. A subdepressor low dose of rampril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis. 1999;33:450-7.
18. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophisiology. Ann Intern Med. 1992;117:234-42.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-71.
20. Guideline Committee. 2003 European society of hypertension-European society of cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:10011-1053.
21. Remuzzi G, Ruggenenti P, Perico N. Chronic renal disease: renoprotective benefits of rennin-angiotensin system inhibition. Ann Intern Med. 2002;136:604-15.
22. Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans. Kidney Int. 1996;50:684-92.
23. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1922;90:766.
24. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa T, Fogo A. Blood pressure-independent effect of angiotensin inhibition on the glomerular and non-glomerular vascular lesions of chronic renal failure. Kidney Int. 1992;42:46.
25. Zoja C, Donadelli R, Coma D, Testa D, Facchinetti D, Maffi R, et al. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are soley due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis. 1997;29:254.
26. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol. 1998;9:224.
27. Hutchison FN, Cui X, Webster SK. The antiproteinuric action on angiotensin -converting enzyme in dependent on kinin. J Am Soc Nephrol. 1995;6:1216-22.
28. Bascands J, Schanstra JP. Bradykinin and renal fibrosis: have we ACE'd it? J Am Soc Nephrol. 2004;15:2504-6.
29. Okada H, Watanabe Y, Kikuta T, Kobayashi T, Kannno Y, Suguya T, et al. Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstium under angiotensin converting enzyme blockade. J Am Soc Nephrol. 2004;15:2404-13.
30. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992;1:1-17.
31. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40:141-4.
32. Bakris GL, Weir MR, Secic M, Cambell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002.
33. Schieppati A, Remuzzi G. The future renoprotection: frustration and promises. Kidney Int. 2003;64:1947-55.